INFO & CONTACTS:  +39 02 2390 1

An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab
Deruxtecan Monotherapy versus Treatment of Physician’s Choice in
Hormone Receptorpositive, HER2-negative Unresectable Locally Advanced or
Metastatic Breast Cancer (HERTHENA-Breast04)

Phase: Phase II-III clinical trials

Principal Investigator: Prof. Vernieri Claudio

Main Facility: Oncologia Medica 1

Drug: Patritumab Deruxtecan

Pathologies: Breast cancer

ClinicalTrials.gov: Read more about clinical trials

he study is a Phase III, multicenter, interventional, non-randomized, openlabel, single-arm clinical trial evaluating patients with advanced or metastatic breast cancer, specifically HR+/HER2- or HER2-low, who have previously been treated with standard therapies. The study design involves a single arm, in which patients receive patritumab deruxtecan, an antibody-drug conjugate (ADC) directed against HER3, administered intravenously. The objective of the study is to evaluate the drug's antitumor activity, in terms of objective response rate (ORR), as well as secondary parameters such as progression-free survival (PFS), duration of response (DoR), and safety profile.

Last update: 12/05/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe